Clinical Trial Update: Clinical Study of Adjuvant Surufatinib Therapy for Postoperative High-risk Neuroendocrine Tumors Based on the Ninth Edition of the AJCC Staging System [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating adjuvant surufatinib for postoperative high-risk neuroendocrine neoplasms under the AJCC 9th edition staging; currently not ye…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Neuroendocrine Neoplasms

Drugs mentioned

• Surufatinib (Surufatinib)

Snippet

Sponsor: Second Affiliated Hospital, School of Medicine, Zhejiang University | Conditions: Neuroendocrine Neoplasms (Tumours) | Phase 2 | Status: NOT_YET_RECRUITING